AG
CALA

Artal Group’s Calithera Biosciences, Inc CALA Stock Holding History

Artal Group’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,000
Closed -$835K – 142
2017
Q4 		$835K Sell
5,000
-3,750
-43% -$960K 0.01% 115
2017
Q3 		$2.76M Sell
8,750
-1,250
-13% -$394K 0.05% 85
2017
Q2 		$2.97M Buy
+10,000
New +$2.67M 0.05% 84

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Artal Group's CALA Position: Q1 2018 in Review

Artal Group sold out of Calithera Biosciences, Inc (CALA) in Q1 2018, closing a stake of 5,000 shares — an estimated $835K sold.

Artal Group first reported a position in CALA in Q2 2017 and held it in 3 quarters. The position peaked at $2.97M in Q2 2017. 100 funds tracked by Wall St. Rank hold CALA as of Q1 2018.

  • Artal Group reported no remaining Calithera Biosciences, Inc position as of Q1 2018 after selling out during the quarter.
  • Artal Group sold 5,000 Calithera Biosciences, Inc shares in Q1 2018, an estimated $835K.
  • Artal Group first reported a position in Calithera Biosciences, Inc in Q2 2017 and held it in 3 quarters.
  • Artal Group's Calithera Biosciences, Inc position peaked at $2.97M in Q2 2017.
  • 100 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.